Novel PEI-aldehyde conjugates for gene delivery: Promoting chondrogenic differentiation in human mesenchymal stem cells.

IF 6.1 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Molecular Therapy. Nucleic Acids Pub Date : 2025-04-29 eCollection Date: 2025-06-10 DOI:10.1016/j.omtn.2025.102551
Diego Miranda-Balbuena, Alba Ramil-Bouzas, Naiara Doldán-Mata, Junquera López-Seijas, Juan Fafián-Labora, Ibán Lamas-Criado, Jose-Ramón Caeiro-Rey, Paco Fernández-Trillo, Ana Rey-Rico
{"title":"Novel PEI-aldehyde conjugates for gene delivery: Promoting chondrogenic differentiation in human mesenchymal stem cells.","authors":"Diego Miranda-Balbuena, Alba Ramil-Bouzas, Naiara Doldán-Mata, Junquera López-Seijas, Juan Fafián-Labora, Ibán Lamas-Criado, Jose-Ramón Caeiro-Rey, Paco Fernández-Trillo, Ana Rey-Rico","doi":"10.1016/j.omtn.2025.102551","DOIUrl":null,"url":null,"abstract":"<p><p>Mesenchymal stem cell (MSC) gene therapy holds significant potential for regenerative medicine, especially for treating conditions such as cartilage damage. Still, finding appropriate vectors to achieve a safe and efficient gene delivery remains a challenge. This study explores the development of novel polyethyleneimine (PEI)-based polymers functionalized with both cationic guanidinium and hydrophobic aldehyde groups for efficient transfection to human MSCs (hMSCs). PEI was chemically modified with guanidinium-(3-guanidin-N-(3-oxopropyl)propanamide [T1]) and 1-(4-formylphenyl)guanidine [T2]) and hydrophobic (octanal [T3A] and dodecanal [T3B]) aldehydes. Polyplexes were formed by the complexation of PEI-aldehyde conjugates with plasmids encoding for β-galactosidase (p<i>lacZ</i>), green fluorescent protein (pGFP), and the chondrogenic transcription factor SOX9 (p<i>sox9</i>), and demonstrated efficient DNA complexation and protection. Among the formulations, PEI functionalized with the cationic (T2) and hydrophobic (T3A) aldehydes (PEIT2T3A) exhibited a superior transfection efficiency and biocompatibility, significantly enhancing the expression of target genes in hMSCs. Importantly, PEIT2T3A/p<i>sox9</i> polyplexes successfully promoted the chondrogenic differentiation of hMSCs, as evidenced by the increased expression of chondrogenic markers (SOX9, type-II collagen [COLII], and aggrecan [ACAN]) and proteoglycan deposition in aggregate cultures, while mitigating the low cell viability found with unmodified PEI. These findings suggest that PEIT2T3A is a promising non-viral vector for targeted gene delivery and hMSC-based regenerative medicine applications.</p>","PeriodicalId":18821,"journal":{"name":"Molecular Therapy. Nucleic Acids","volume":"36 2","pages":"102551"},"PeriodicalIF":6.1000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141052/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Nucleic Acids","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtn.2025.102551","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/10 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Mesenchymal stem cell (MSC) gene therapy holds significant potential for regenerative medicine, especially for treating conditions such as cartilage damage. Still, finding appropriate vectors to achieve a safe and efficient gene delivery remains a challenge. This study explores the development of novel polyethyleneimine (PEI)-based polymers functionalized with both cationic guanidinium and hydrophobic aldehyde groups for efficient transfection to human MSCs (hMSCs). PEI was chemically modified with guanidinium-(3-guanidin-N-(3-oxopropyl)propanamide [T1]) and 1-(4-formylphenyl)guanidine [T2]) and hydrophobic (octanal [T3A] and dodecanal [T3B]) aldehydes. Polyplexes were formed by the complexation of PEI-aldehyde conjugates with plasmids encoding for β-galactosidase (placZ), green fluorescent protein (pGFP), and the chondrogenic transcription factor SOX9 (psox9), and demonstrated efficient DNA complexation and protection. Among the formulations, PEI functionalized with the cationic (T2) and hydrophobic (T3A) aldehydes (PEIT2T3A) exhibited a superior transfection efficiency and biocompatibility, significantly enhancing the expression of target genes in hMSCs. Importantly, PEIT2T3A/psox9 polyplexes successfully promoted the chondrogenic differentiation of hMSCs, as evidenced by the increased expression of chondrogenic markers (SOX9, type-II collagen [COLII], and aggrecan [ACAN]) and proteoglycan deposition in aggregate cultures, while mitigating the low cell viability found with unmodified PEI. These findings suggest that PEIT2T3A is a promising non-viral vector for targeted gene delivery and hMSC-based regenerative medicine applications.

用于基因传递的新型倍醛偶联物:促进人间充质干细胞的软骨分化。
间充质干细胞(MSC)基因治疗在再生医学方面具有巨大的潜力,特别是在治疗软骨损伤等疾病方面。然而,找到合适的载体来实现安全有效的基因传递仍然是一个挑战。本研究探索了新型聚乙烯亚胺(PEI)基聚合物的开发,该聚合物具有阳离子胍和疏水性醛基团,可用于高效转染人间充质干细胞(hMSCs)。PEI用胍-(3-胍- n-(3-氧丙基)丙酰胺[T1])和1-(4-甲酰苯基)胍[T2]和疏水性(辛醛[T3A]和十二醛[T3B])醛进行化学修饰。pei -醛偶联物与编码β-半乳糖苷酶(placZ)、绿色荧光蛋白(pGFP)和软骨生成转录因子SOX9 (psox9)的质粒络合形成多聚体,并表现出有效的DNA络合和保护作用。其中,阳离子醛(T2)和疏水性醛(T3A)功能化的PEI (PEIT2T3A)具有较好的转染效率和生物相容性,显著提高了靶基因在hMSCs中的表达。重要的是,PEIT2T3A/psox9多聚体成功地促进了hMSCs的软骨分化,这可以通过软骨标志物(SOX9、ii型胶原[COLII]和聚集蛋白[ACAN])的表达增加和聚集培养物中的蛋白多糖沉积来证明,同时减轻了未修饰PEI的低细胞活力。这些发现表明PEIT2T3A是一种很有前景的靶向基因传递和基于hmsc的再生医学应用的非病毒载体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
15.40
自引率
1.10%
发文量
336
审稿时长
20 weeks
期刊介绍: Molecular Therapy Nucleic Acids is an international, open-access journal that publishes high-quality research in nucleic-acid-based therapeutics to treat and correct genetic and acquired diseases. It is the official journal of the American Society of Gene & Cell Therapy and is built upon the success of Molecular Therapy. The journal focuses on gene- and oligonucleotide-based therapies and publishes peer-reviewed research, reviews, and commentaries. Its impact factor for 2022 is 8.8. The subject areas covered include the development of therapeutics based on nucleic acids and their derivatives, vector development for RNA-based therapeutics delivery, utilization of gene-modifying agents like Zn finger nucleases and triplex-forming oligonucleotides, pre-clinical target validation, safety and efficacy studies, and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信